New findings could tackle over-diagnosis and over-treatment of breast cancer

December 4, 2013
New findings could tackle over-diagnosis and over-treatment of breast cancer

New research from Queen Mary University of London has revealed, for the first time, the molecule αvβ6 (alpha v beta 6) could tell doctors which cases of Ductal Carcinoma in Situ (DCIS), a condition where non-invasive cancerous cells are contained within the milk ducts of the breast, are most likely to develop into early 'invasive' breast cancer.

Around 4,800 cases of DCIS are diagnosed each year in the UK, with two thirds diagnosed through . If left untreated, up to half of DCIS cases could progress into invasive breast cancer but it is not possible to say which ones. This means all women are offered treatment and faced with the difficult decision of whether to have it or not.

The study, funded by Breast Cancer Campaign, indicates with further research αvβ6 could be used to stratify patient treatment, meaning a significant proportion of the 4,800 women diagnosed with DCIS each year in the UK could avoid unnecessary procedures. This would mean a reduction in the number of women requiring surgery and other treatments such as radiotherapy, addressing the issue of over-diagnosis and over-treatment of the condition.

Researchers looked at 583 breast tissue samples from normal breasts and those with DCIS, and showed there to be a link between levels of αvβ6 in myoepithelial cells (cells which form part of the milk duct walls) and whether breast tissue was normal, had DCIS or had progressed to invasive breast cancer. There was almost no αvβ6 in cells from normal tissues, whereas over half of the DCIS cases had αvβ6 in the surrounding cells (52% of non-high grade DCIS and 69% of high grade DCIS) and nearly all DCIS cases that had already started to become had αvβ6.

The researchers then looked at a further 104 cases of DCIS matched to long term follow up information on each woman and found that the levels of αvβ6 in patients' myoepithelial cells were strongly associated with their DCIS recurring or progressing, and this effect was seen independently of the grade and size of the DCIS.

Women whose myoepithelial cells contained αvβ6 saw their disease recur around nine years earlier than those without αvβ6; cases with αvβ6 recurred in an average of 2.3 years compared to 11.4 years for those without αvβ6.

Professor Louise Jones, Professor of Breast Pathology at Queen Mary University of London's Barts Cancer Institute, comments:

"We are confident these results will be validated in further studies and from there we don't envisage any barriers to this research resulting in the development of a routine test which could take place in the clinic. This will be a huge step forward in how we treat women with DCIS. Our ultimate goal is that women diagnosed with DCIS without αvβ6 could be offered active monitoring, saving them from potentially unnecessary surgery and radiotherapy."

Further experiments using cell and mouse models showed that αvβ6 encouraged breast cancer cells to spread out and grow much faster. They also revealed that αvβ6 is dependent on two other proteins to promote cancer growth, TGFβ and MMP9, and with further research these could potentially be targeted with drugs to prevent DCIS from progressing.

Dr Michael Allen, Postdoctoral Research Assistant at Queen Mary University of London's Barts Cancer Institute, comments:

"These findings show that we are really starting to find some clarity in the grey areas surrounding the subject of DCIS, and interestingly this insight has come from specialised cells which surround the DCIS, rather than the cancer themselves. There is still much more we need to do, but we have found some important correlations between the presence of the marker, αvβ6, and the progression of DCIS into invasive , and that is very exciting."

Explore further: Breast conserving treatment with radiotherapy reduces risk of local recurrence

More information: Allen, M.D., et al. (2013) Altered Microenvironment Promotes Progression of Pre-Invasive Breast Cancer: myoepithelial expression of αvβ6 integrin in DCIS identifies high-risk patients and predicts recurrence. Clinical Cancer Research. DOI: 10.1158/1078-0432.CCR-13-1504

Related Stories

Breast conserving treatment with radiotherapy reduces risk of local recurrence

September 18, 2013
Results of EORTC trial 10853 appearing in the Journal of Clinical Oncology show that breast conserving treatment combined with radiotherapy reduces the risk of local recurrence in women with ductal carcinoma in situ (DCIS). ...

Terminology used to describe preinvasive breast cancer may affect patients' treatment preferences

August 26, 2013
When ductal carcinoma in situ (DCIS, a preinvasive malignancy of the breast) is described as a high-risk condition rather than cancer, more women report that they would opt for nonsurgical treatments, according to a research ...

DCIS Score quantifies risk of ipsilateral breast event

May 2, 2013
The ductal carcinoma in situ (DCIS) Score quantifies the risk of ipsilateral breast event (IBE) and invasive IBE risk, complements both traditional clinical and pathologic factors, and helps provide a new clinical tool to ...

Combined RB and PTEN loss identifies DCIS primed for invasive breast cancer

November 28, 2012
The combined loss of two tumor suppressor genes, retinoblastoma (RB) and phosphatase and tensin homolog (PTEN) was shown to be strongly associated with progression of DCIS to invasive breast cancer, according to a study published ...

MRI right before or after surgery does not benefit women with early breast cancer

September 4, 2013
Memorial Sloan-Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates. The findings ...

Tests may someday show which breast, prostate cancers will turn aggressive

October 28, 2013
(HealthDay)—Doctors believe they have found telltale signs that can indicate whether breast or prostate malignancies will remain dormant or develop into aggressive cancers.

Recommended for you

Vitamin C may encourage blood cancer stem cells to die

August 17, 2017
Vitamin C may "tell" faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.